Consolidated Balance Sheets (Parentheticals) - USD ($) $ / shares in Thousands, $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Unrestricted cash and cash equivalents	$ 409,660	$ 178,102
Restricted cash and cash equivalents	96,968	80,859
Loans, interest and fees receivable, at fair value	1,026,424	417,098
Loans, interest and fees receivable, gross	470,293	667,556
Allowances for uncollectible loans, interest and fees receivable	57,201	124,961
Deferred revenue	29,281	39,456
Notes payable, at face value	$ 1,278,864	$ 882,610
Preferred stock, par value (in dollars per share)	$ 0	$ 0
Common stock, par value (in dollars per share)	$ 0	$ 0
Common stock, authorized (in shares)	150,000,000	150,000,000
Common stock, issued (in shares)	14,804,408	16,115,353
Common stock, outstanding (in shares)	14,804,408	16,115,353
Own-share lending arrangement, outstanding (in shares)		1,459,233
Series A Preferred Stock [Member]
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	400,000	400,000
Preferred stock, shares outstanding (in shares)	400,000	400,000
Preferred stock, liquidation preference	$ 40,000	$ 40,000
Series B Preferred Stock [Member]
Preferred stock, no par value (in dollars per share)	$ 0	$ 0
Preferred stock, shares issued (in shares)	3,188,533	0
Preferred stock, shares outstanding (in shares)	3,188,533	0
Preferred stock, liquidation preference	$ 79,700	$ 79,700
Variable Interest Entity, Primary Beneficiary [Member]
Unrestricted cash and cash equivalents	209,500	96,600
Restricted cash and cash equivalents	75,900	70,200
Loans, interest and fees receivable, at fair value	925,500	374,200
Loans, interest and fees receivable, gross	369,600	560,200
Allowances for uncollectible loans, interest and fees receivable	55,100	120,900
Deferred revenue	8,200	10,300
Notes payable, at face value	$ 1,223,400	$ 827,100